An EGFR/HER2-Bispecific and Enediyne-Energized Fusion Protein Shows High Efficacy against Esophageal Cancer
Esophageal cancer is one of the most common cancers, and the 5-year survival rate is less than 10% due to lack of effective therapeutic agents. This study was to evaluate antitumor activity of Ec-LDP-Hr-AE, a recently developed bispecific enediyne-energized fusion protein targeting both epidermal gr...
Main Authors: | , , , , |
---|---|
Format: | Online |
Language: | English |
Published: |
Public Library of Science
2014
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963964/ |